Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
-1.25% $14.17
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 476.13 mill |
EPS: | -0.200 |
P/E: | -70.85 |
Earnings Date: | May 09, 2024 |
SharesOutstanding: | 33.60 mill |
Avg Daily Volume: | 0.0779 mill |
RATING 2024-03-28 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Buy | |
P/E: | Strong Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | |||
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -70.85 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-12.05x |
Company: PE -70.85 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 13.20 - 15.14 ( +/- 6.83%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-26 | Kim Peter S | Buy | 2 750 | Common Stock |
2024-03-25 | Kim Peter S | Buy | 3 180 | Common Stock |
2024-03-22 | Kim Peter S | Buy | 3 118 | Common Stock |
2024-03-21 | Kim Peter S | Buy | 704 | Common Stock |
2024-03-20 | Kim Peter S | Buy | 1 128 | Common Stock |
INSIDER POWER |
---|
68.13 |
Last 99 transactions |
Buy: 990 980 | Sell: 225 368 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $14.17 (-1.25% ) |
Volume | 0.102 mill |
Avg. Vol. | 0.0779 mill |
% of Avg. Vol | 130.41 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:18 | sell | $14.52 | N/A | Active |
---|
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.